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Abstract 
The  desmoplastic  small  round  cell  tumor
(DSRCT) is an uncommon and highly aggres-
sive cancer. The role of 
18F-FDG PET in man-
agement of DSRCT is little reported. We report
a  case  of  metastasized  abdominal  DSRCT
detected in a 43-year old patient whose diag-
nostic and therapeutic approaches were influ-
enced by 
18F-FDG PET-CT. The patient is still
alive ten years after diagnosis. 
18F-FDG PET-CT
seems  to  be  a  useful  method  for  assessing
therapeutic  efficiency  and  detecting  early
recurrences even in rare malignancies such as
DSRCT.
Introduction
The  desmoplastic  small  round  cell  tumor
(DSRCT)  is  an  extremely  rare  and  highly
aggressive neoplasm mainly affecting adoles-
cents and young male adults.
1,2 DSRCT origi-
nates predominantly in the abdominal or pelvic
cavity,  spreading  along  the  peritoneum  with
organ  involvement  and  secondary  phenome-
na.
3 Despite multimodality aggressive therapy,
patient prognosis is unfavorable, with a medi-
an survival of less than 30 months. Only a few
long-term survivors are reported.
4,5
To  our  knowledge,  no  definitive  standard
recommendations  exist  concerning  DSRCT
treatment and patient management during fol-
low-up.
3 X-ray  Computed  Tomography  (CT)
remains  the  first  choice  imaging  modality
employed in patients affected by DSRCT. 
18F-
fluoro-2-deoxy-D-glucose  positron  emission
tomography  (
18F-FDG  PET)  is  a  functional
imaging  technique  widely  used  in  clinical
oncology because of its high diagnostic accura-
cy.
6 However, the role of 
18F-FDG PET in the
management of DSRCT is little described.
We  report  a  rare  case  of  a  metastasized
abdominal  DSRCT  detected  in  a  43-year  old
patient  whose  diagnostic  and  therapeutic
strategies were influenced by the 
18F-FDG PET-
CT. The patient is still alive at the time of this
report, ten years after the diagnosis.
Case Report
A 43-year old man with a history of right kid-
ney cysts was referred to our Institution for
further  evaluation  of  a  preaortic  intraperi-
toneal  mass  incidentally  detected  during
abdominal ultrasonography. Clinical examina-
tion and routine biological evaluation showed
no  remarkable  findings.  Media  contrast
enhancement (mce) CT of the abdomen and
pelvis showed the presence of a vascularized,
preaortic  mass  (7x5  cm)  associated  to
retroperitoneal lymphadenopathy and mesen-
teric nodules, for which the diagnosis of malig-
nancy was evoked. Chest mce-CT showed nei-
ther  pathological  lymphadenopathy  nor  lung
parenchyma abnormalities. The serum level of
common  tumoral  markers  was  normal.  The
results of 24 h urine analysis showed normal
concentrations of dopamine, epinephrine and
norepinephrine. A whole body (WB) bone scan
showed no pathological foci of tracer uptake.
An ultrasound guided needle biopsy of preaor-
tic lesion was made for pathological evalua-
tion.  Microscopic  examination  revealed  neo-
plastic proliferation of small cells with abun-
dant  and  clear  cytoplasm.  The  nuclei  were
slightly increased in size, oval, hyperchromat-
ic, and with inconspicuous nucleoli. The tumor
cells were surrounded by fibro-sclerotic stro-
ma.  The  immunohistochemical  studies
revealed that the tumor cells were positive for
antibodies  against  keratin,  epithelial  mem-
brane antigen, vimentin, desmin and focally
neuron specific enolase. Tumoral proliferation
index, estimated with antibodies against Ki-
67, was elevated (50%). Both the histological
aspect and immunohistochemical profile lead
to  the  diagnostic  hypothesis  of  DSRCT.  The
molecular  analysis  found  no  specific  gene
translocation  t(11;22)(p13;q12).  In  October
1999, the patient underwent surgery including
tumoral radical resection, partial sigmoidecto-
my,  and  primitive  iliac  and  peri-aortic  lym-
phadectomy.  Microscopic  analysis  of  the
excised  tumor  confirmed  biopsy  suspicion;
thus  metastatic  DSRCT  was  retained  as  the
final diagnosis.
Treatment was carried out according to the
99  EURO-EWING  protocol.
7 From  December
1999 to April 2000 the patient received 6 cycles
of  VIDE  combining  intravenous  (i.v.)  vin-
cristine (1.5 mg/m
2on day 1), ifosfamide (3000
mg/m
2 on day 1-3), doxorubicin (20 mg/m
2 on
day 1-3) and etoposide (150 mg/m
2 on day 1-3).
The sequence was repeated every three weeks.
No concomitant radiotherapy was performed.
Morphological imaging (CT) performed after 4
and 6 cycles of treatment demonstrated com-
plete remission. No other radiological lesion
was described.
In  September  2003,  retroperitoneal  lym-
phadenophathy was detected on CT study and
biopsied.  Microscopic  examination  revealed
lymphatic DSRCT relapse. Radiological partial
remission was obtained after 3 cycles of VIDE,
thus 12 cycles i.v. of irinotecan (180 mg/m
2 on
day 1, every two weeks) were administered as
a second-line chemotherapy. In an attempt to
determine the response to therapy, the patient
underwent  whole-body  (WB) 
18F-FDG  PET
examination (Figure 1a). A combined PET-CT
scanner  was  employed  (Discovery  ST,  GE
Medical  System;  Milwaukee,  USA).  PET-CT
acquisitions started 60 min after tracer injec-
tion (5.5 MBq/kg), including a head to thighs
CT followed by a 2D PET. CT, PET (attenuation
corrected) and fusioned PET-CT images were
displayed and visually interpreted. For quanti-
tative analysis of 
18F-FDG tumoral uptake, we
use the maximum standardized uptake value
(mSUV) per focus. In all of the PET studies
performed, the mSUV was measured in the foci
of  highest 
18F-FDG  uptake  within  the  tumor.
Those values were then considered for tumor
residual viability assessment. 
18F-FDG PET-CT
showed several retroperitoneal lymphadenopa-
thy  with  pathological  glucidic  hypermetabo-
lism,  inducing  modification  of  chemothera-
peutic strategy. Three cycles of actinomicine
(2.5 mg/m
2 on day 1, every three weeks) were
performed without any considerable effect on
tumoral  progression.  Thereafter,  the  patient
was treated by VIP 500, combining i.v. etopo-
side (100 mg/m
2 on day 1-5), ifosfamide (1200
mg/m
2 on day 1-5) and cisplatine (20 mg/m
2 on
day  1-5).  The  sequence  was  repeated  every
three  weeks.  WB 
18F-FDG  PET-CT  study  was
performed after the completion of the first 2 of
6 cycles of VIP 500, to assess early response to
therapy. A limited area of residual abnormal
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glucidic hypermetabolism within the reduced
tumoral mass was recorded on PET-CT images.
No other abnormal hypermetabolic spots sug-
gestive of metastatic localizations were detect-
ed. The patient was considered to be a positive
responder  to  treatment;  thus  chemotherapy
was completed and followed by oral adminis-
tration of etoposide 50 mg daily. A follow-up 
18F-
FDG  PET-CT  performed  in  September  2005
demonstrated complete regression of the trac-
er uptake abnormalities above retroperitoneal
lymphadenopathy detected on previous exami-
nation and morphologically unchanged, so the
treatment  was  stopped  (Figure  1b).  In
December, the PET-CT study showed no active
disease, and the patient was considered to be
in remission. 
In  June  2006,  a  follow-up  PET-CT  study
showed  pathological 
18F-FDG  uptake  within
several  retroperitoneal  lymphadenopathy  of
one centimeter of maximal diameter, consis-
tent with second tumoral relapse (Figure 1c).
Thus, the patient was treated by oral etoposide
50  mg  daily  and  corticoids  100  mg,  day  1-5
monthly. Follow-up scintigraphic examination
was performed in July 2007, demonstrating the
persistence of hypermetabolic retroperitoneal
lymphadenopathy  (Figure  1d).  The  same
chemotherapy  was  continued  including  oral
etoposide 50 mg daily, 3-4 days weekly accord-
ing to the hematologic results, associated to
corticoids 100 mg, day 1-5 monthly. The patient
is still alive at the time of this report, ten years
after the diagnosis.
Discussion
DSRCT  is  a  rare  and  highly  aggressive
malignancy of still unknown etiopathogenesis,
first described in 1989 by Gerald and Rosai.
8 In
1991, it was proposed as a distinct entity with
well-recognized  histological  features,  kary-
otype  and  immunochemical  characteristics
with coexpression of epithelial, mesenchymal
and neural markers.
1,4,9 DSRCT has a predilec-
tion for adolescent and young adult males, with
a  median  age  of  22  years.
10 The  majority  of
DSCRT occurs in the abdominal cavity, includ-
ing  retroperitoneum,  pelvis,  omentum  and
mesentery as primary origin site. Some cases
had presentation sites in the scrotum, pleura,
lung, mediastenum, chest wall, thigh, intracra-
nial, soft tissue, sino-nasal regions, submen-
tal, parotid gland and kidney.
11-19
DSCRT  are  characterized  by  multinodular
growth on the serosal surface.
11,20These tumors
have  a  tendency  to  spread  along  the  peri-
toneum  and  mesothelial-lined  surfaces  with
organ  involvement  and  secondary  phenome-
na.
3 The most frequent sites of metastasis are
the  liver,  lymph  nodes,  lung  and  bone  mar-
row.
3,9,21 This pattern of disease spread reveals
the predilection of these tumors to metastasize
through both the lymphatic and hematogenous
routes.
3 In our clinical observation, metastatic
proliferation was essentially lymphatic, with-
out soft tissue or bone involvement.
DSCRT  are  frequently  characterized  by  a
recurrent  specific  translocation  t(11;22)
(p13;q12), resulting in a fusion gene between
Ewing’s sarcoma gene and Wilm’s tumor gene.
5
Nevertheless, according to several reports,
19,22
no  specific  gene  translocation  was  found  in
our patient. 
Because of the rarity of this tumor, only case
reports and small series of patients are docu-
mented, thus no consensus exists concerning
standard methods for its diagnosis, treatment
and management.
3
Although magnetic resonance imaging has
been reported to be more useful than other
radiological  techniques  in  delineating  the
extent of the abdominal and pelvic disease,
19
CT remains the radiological investigation of
first choice. DSCRT appear as single, or multi-
ple,  lobulated  soft  tissue  masses  within  the
omentum, mesentery, perisplenic space, par-
avesical  region,  retroperitoneum  and  in  the
scrotum.
4,21
The  usefulness  of 
18F-FDG  PET-CT  in  the
management of patients affected by DSRCT is
scarcely reported. Dimitrakopoulou-Strauss et
al.,
23 recently suggested 
18F-FDG PET-CT as a
valuable diagnostic tool for monitoring thera-
peutic  effect  in  patients  with  metastasized
DSRCT  treated  by  inhibitors  of  mammalian
target of rapamycin (mTOR). In the report of
Rosoff  et  al.,
24 18F-FDG  PET-CT  was  explored
with  the  aim  of  assessing  the  therapeutic
effect of irinotecan in a patient with DSRCT
showing  residual  mass,  morphologically
unchanged on CT images. PET-CT showed no
evidence  of  active  disease,  especially  above
pelvic  tumor,  demonstrating  complete  treat-
ment efficacy. 
18F-FDG PET accuracy is higher
than that of CT in the assessment of a viable
tumor after chemoradiation treatment, in par-
ticular in lymphomas.
25 Moreover, the sensitiv-
ity of a sole morphological approach may be
reduced  in  normal-sized  metastatic  lymph
node detection, considering size as the princi-
pal diagnostic criteria for tumor involvement.
Our results are in accordance with those found
by Rosoff et al.,
24 showing no pathological 
18F-
FDG uptake in PET images above stable lym-
phadenopathy on CT slices, after the comple-
tion of chemotherapy. The non-invasive nature
of PET and its ability to detect early responses
to therapy make it an ideal modality to evalu-
ate the effectiveness of chemotherapy.
Prognosis of patients affected by DSRCT is
extremely poor, with a median survival of less
than 30 months and a rate of 3- and 5-year sur-
vival of 29% and 15%, respectively.
5,21 The long
survival observed in our patient is largely supe-
rior to the survival reported in the literature.
18F-FDG  PET-CT  played  an  important  role  in
patient  management,  allowing  detection  of
early  recurrence  of  disease  and  consequent
change in chemotherapeutic strategy. The rel-
atively long disease free interval of 42 months
may be due to complete tumoral resection fol-
lowed by adjuvant chemotherapy.
3,5 The inva-
sive and disseminated nature of the disease
makes radical resection difficult to achieve
3,9
with  consequent  worse  patient  prognosis.
Furthermore,  chemotherapeutic  agents  are
only temporarily effective in treating DSRCT
and no consistent response to chemotherapy
has  been  described.
9 Patients  who  present
extra-abdominal tumors that are amenable to
complete surgical resection appear to have a
better  prognosis.
19 In  the  series  reported  by
Saab et al.,
19 2 patients with extra-abdominal
tumors had no evidence of disease at eight and
ten years, respectively. 
Case Report
Figure 1. Whole-body maximum intensity projection 
18F-FDG PET-CT images in 43-year
old patient with DSRCT showing: (a) first relapse, (b) complete temporary remission
after chemotherapy, (c) second relapse, (d) with moderate response to medical treatment.[Rare Tumors 2009; 1:e19] [page 55]
Conclusions
The  optimal  management  for  DSRCT
remains to be determined. The usefulness of
non-invasive metabolic imaging modality, such
as 
18F-FDG PET-CT, may improve the prognosis
of  DSRCT  patients  by  detecting  tumoral
relapse  earlier  than  conventional  anatomic
imaging.  Additional  prospective  studies  are
needed to confirm these results, assessing the
validity  of  a  morpho-functional  approach  in
DSRCT management.
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